Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bariatrix lawsuits

This article was originally published in The Tan Sheet

Executive Summary

Canadian nutritional bar manufacturer has filed separate lawsuits alleging Rexall Sundown, Elan Nutrition "have been and still are infringing" on Bariatrix' patent covering nutritional, confectionery bars that are high in protein. Filed in Burlington, Vt. federal court, suits claim Bariatrix has met with both firms to no avail. "Although the parties discussed the possibility of Rexall's entering into an appropriate license agreement with Bariatrix with respect to the '929 patent, such an agreement ultimately was not consummated," complaint claims. Firm seeks "preliminary and permanent injunction" against Rexall, Elan, as well as "award of damages in favor of Bariatrix...sufficient to compensate" for the patent infringement. Bars in question include Elan's Promax, Rexall's Met-Rx, Carb Solutions, Pure Protein...

You may also be interested in...



US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel